ONT 10

Drug Profile

ONT 10

Alternative Names: BGLP-40; L-BGLP40

Latest Information Update: 17 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomira
  • Developer Celldex Therapeutics Inc; Oncothyreon
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Breast cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 03 May 2018 Immunovaccine is now called IMV
  • 05 Nov 2015 Discontinued - Phase-I for Breast cancer (Combination therapy, Late-stage disease) in USA (SC)
  • 05 Nov 2015 Discontinued - Phase-I for Ovarian cancer (Combination therapy, Late-stage disease) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top